Eganelisib
Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases[1].
Product Specifications
CAS Number
[1693758-51-8]
Product Name Alternative
IPI-549
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/IPI549.html
Concentration
10mM
Purity
99.68
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1=C2N=CC=CN2N=C1N)N[C@H](C3=CC4=C(C(N3C5=CC=CC=C5)=O)C(C#CC6=CN(C)N=C6)=CC=C4)C
Molecular Formula
C30H24N8O2
Molecular Weight
528.56
Precautions
H302, H315, H319, H335
References & Citations
[1]Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K) -γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7 (9) :862-7.|[2]De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Nov 17;539 (7629) :443-447.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PI3Kα; PI3Kβ; PI3Kγ
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
